Literature DB >> 11395384

p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

D A Tweddle1, A J Malcolm, M Cole, A D Pearson, J Lunec.   

Abstract

This study investigated the hypothesis that p53 accumulation in neuroblastoma, in the absence of mutation, is associated with functional inactivation, which interferes with downstream mediators of p53 function. To test this hypothesis, p53 expression, location, and functional integrity was examined in neuroblastoma by irradiating 6 neuroblastoma cell lines and studying the effects on p53 transcriptional function, cell cycle arrest, and induction of apoptosis, together with the transcriptional function of p53 after irradiation in three ex vivo primary, untreated neuroblastoma tumors. p53 sequencing showed five neuroblastoma cell lines, two of which were MYCN-amplified, and that all of the tumors were wild-type for p53. p53 was found to be predominantly nuclear before and after irradiation and to up-regulate the p53 responsive genes WAF1 and MDM2 in wild-type p53 cell lines and a poorly-differentiated neuroblastoma, but not a differentiating neuroblastoma or the ganglioneuroblastoma part of a nodular ganglioneuroblastoma in short term culture. This suggests intact p53 transcriptional activity in proliferating neuroblastoma. Irradiation of wild-type p53 neuroblastoma cell lines led to G(1) cell cycle arrest in cell lines without MYCN amplification, but not in those with MYCN amplification, despite induction of WAF1. This suggests MYCN amplification may alter downstream mediators of p53 function in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395384      PMCID: PMC1892004          DOI: 10.1016/S0002-9440(10)64678-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Response of neuroblastoma to retinoic acid in vitro and in vivo.

Authors:  C P Reynolds; D J Kane; P A Einhorn; K K Matthay; V L Crouse; J R Wilbur; S B Shurin; R C Seeger
Journal:  Prog Clin Biol Res       Date:  1991

3.  Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.

Authors:  A M Davidoff; J C Pence; N A Shorter; J D Iglehart; J R Marks
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

4.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.

Authors:  J L Biedler; S Roffler-Tarlov; M Schachner; L S Freedman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

5.  Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities.

Authors:  N Ikegaki; J Bukovsky; R H Kennett
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

6.  Biological classification of cell lines derived from human extra-cranial neural tumors.

Authors:  C P Reynolds; M M Tomayko; L Donner; L Helson; R C Seeger; T J Triche; G M Brodeur
Journal:  Prog Clin Biol Res       Date:  1988

7.  Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells.

Authors:  N Sidell; H P Koeffler
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

8.  Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: involvement of bcl-2 and p53 proteins.

Authors:  K Tieu; D M Zuo; P H Yu
Journal:  J Neurosci Res       Date:  1999-11-01       Impact factor: 4.164

9.  Immunoaffinity chromatography of a cellular tumor antigen from mouse neuroblastoma cells.

Authors:  K Levitsky; K Chandrasekaran; P T Mora; D T Simmons
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

10.  Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin.

Authors:  J C Reed; L Meister; S Tanaka; M Cuddy; S Yum; C Geyer; D Pleasure
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

View more
  30 in total

1.  Closing the phenotypic gap between transformed neuronal cell lines in culture and untransformed neurons.

Authors:  Tereance A Myers; Cheryl A Nickerson; Deepak Kaushal; C Mark Ott; Kerstin Höner zu Bentrup; Rajee Ramamurthy; Mayra Nelman-Gonzalez; Duane L Pierson; Mario T Philipp
Journal:  J Neurosci Methods       Date:  2008-07-10       Impact factor: 2.390

2.  TDP-43 regulates the microprocessor complex activity during in vitro neuronal differentiation.

Authors:  Valerio Di Carlo; Elena Grossi; Pietro Laneve; Mariangela Morlando; Stefano Dini Modigliani; Monica Ballarino; Irene Bozzoni; Elisa Caffarelli
Journal:  Mol Neurobiol       Date:  2013-10-11       Impact factor: 5.590

3.  p53 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Lindi Chen; Nunzio Iraci; Samuele Gherardi; Laura D Gamble; Katrina M Wood; Giovanni Perini; John Lunec; Deborah A Tweddle
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

4.  Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.

Authors:  Lauren A Gillory; Jerry E Stewart; Michael L Megison; Alicia M Waters; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2015-03-14       Impact factor: 2.192

5.  Peroxisome proliferator-activated receptor-β/δ inhibits human neuroblastoma cell tumorigenesis by inducing p53- and SOX2-mediated cell differentiation.

Authors:  Pei-Li Yao; Liping Chen; Tomasz P Dobrzański; Bokai Zhu; Boo-Hyon Kang; Rolf Müller; Frank J Gonzalez; Jeffrey M Peters
Journal:  Mol Carcinog       Date:  2017-01-13       Impact factor: 4.784

6.  Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis.

Authors:  C S Coleman; J P Rocetes; D J Park; C J Wallick; B J Warn-Cramer; K Michel; R Dudler; A S Bachmann
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

7.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Authors:  Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

8.  Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy.

Authors:  Danny Rogers; Karen D Nylander; Zhiping Mi; Tong Hu; Nina F Schor
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-13       Impact factor: 3.333

9.  Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Authors:  Zaowen Chen; Yunfu Lin; Eveline Barbieri; Sue Burlingame; John Hicks; Andrew Ludwig; Jason M Shohet
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

10.  Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.

Authors:  Tom Van Maerken; Devanand Sarkar; Frank Speleman; Paul Dent; William A Weiss; Paul B Fisher
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.